Raymond James reiterated its Strong Buy rating and $125 price target on Dianthus after the company reported strong early data from the Phase 3 CAPTIVATE study of claseprubart in CIDP.
Sanofi discontinues its Phase 3 MOBILIZE study of riliprubart in refractory CIDP after failing to show efficacy. The setback raises major doubts for Dianthus’ claseprubart (C1s inhibitor).
Dianthus shares surged after an early “GO” decision in Phase 3 CAPTIVATE trial of claseprubart for CIDP. Strong 50%+ response rate and clean safety profile reported. Top-line data expected by end of 2026.
Dianthus's Claseprubart shows promising Phase 2 results for gMG, significantly improving daily activities & muscle strength with good safety. Plans for a convenient self-administered dose and a Phase 3 trial in 2026.
